Delivery Order SPE2DB22D3011-SPE2DB25FQ2UN
- Not listed
- The Defense Logistics Agency awarded a $3,210.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ryanodex 250 mg vials, with an ultimate completion date of August 13, 2025. This non-set-aside contract was competitively awarded on July 23, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Ryanodex is a dantrolene sodium formulation used primarily for the acute treatment of malignant hyperthermia in surgical settings, representing a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Ryanodex 250 mg vials, with a ceiling value of $1,605.44 and an ultimate completion date of October 6, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ryanodex 250 mg vials valued at $9,632.64. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a non-competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is listed as...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $6,421.76 firm fixed-price delivery order for 250 mg vials of Ryanodex, a muscle relaxant used primarily in anesthesia and critical care settings. This non-competitive delivery order, issued on June 20, 2025, with an ultimate completion date of July 14, 2025, will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $9,632.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ryanodex 250 mg vials. This is a non-set-aside, competitively awarded contract with an ultimate completion date of July 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ryanodex is a rapid-sequence intubation agent used in emergency...
- The Defense Logistics Agency awarded a delivery order valued at $9,632.64 to AmerisourceBergen Drug Corp for Ryanodex 250 mg vials, with an ultimate completion date of June 11, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ryanodex 250 mg vials, with a ceiling value of $3,210.88 and a completion date of October 3, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to AmerisourceBergen's Corporate Office division, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The award is issued under...
- The Defense Logistics Agency awarded a $1,605.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ryanodex 250 mg vials. The contract was competitively awarded with no set-aside designation and carries an ultimate completion date of August 26, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ryanodex 250mg vials with a firm fixed price ceiling value of $57,795.84 and an ultimate completion date of August 18, 2025. This is a non-set-aside, competitively awarded contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 250 mg vials of Ryanodex, a pharmaceutical product used in acute care and anesthesia settings. This $1,605.44 firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 19, 2025. The contract represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This delivery order is a child...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2UNDelivery Order
The Defense Logistics Agency awarded a $1,605.44 delivery order to AmerisourceBergen Drug Corp for the supply of Ryanodex 250 mg vials. This firm fixed-price contract, which was not set-aside and competitively awarded, is scheduled for completion by October 8, 2025. Ryanodex (dantrolene sodium) is a rapid-onset muscle relaxant used in acute medical settings, particularly for malignant hyperthermia management in military and veteran healthcare systems. The product will be performed and shipped from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies globally. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across defense and veteran healthcare systems. The company's role as a prime contractor under this DLA framework demonstrates its capability to meet federal pharmaceutical supply requirements through competitive award processes and deliver specialized medical commodities to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/17/25 |